Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028008 | 0.93 | MTTP (0.46) | MTTPKDM4EMAPTSCDADORA3 | |
| SCHEMBL14028011 | 0.92 | MTTP (0.55) | MTTP | |
| SCHEMBL14028005 | 0.91 | MTTP (0.49) | MTTPPHGDH | |
| SCHEMBL14028021 | 0.85 | MTTP (0.47) | MTTPKDM4EMAPTSCDADORA3 | |
| SCHEMBL14028012 | 0.83 | MTTP (0.54) | MTTPKDM4EMAPT | |
| SCHEMBL14028015 | 0.83 | MTTP (0.57) | MTTP | |
| SCHEMBL14028026 | 0.83 | ROCK2 (0.44) | MTTPKDM4EMAPTSCDADORA3 | |
| SCHEMBL14028014 | 0.82 | MTTP (0.51) | MTTPSCDADORA3ROCK2ROCK1 | |
| SCHEMBL14027938 | 0.80 | MTTP (0.72) | MTTP | |
| SCHEMBL14028001 | 0.79 | MTTP (0.55) | MTTPADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | MTTP 1/4885KDM4E 2386/4885MAPT 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.